Finally, our data suggest tau and SynGAP1 as potential drug targets in acute brain damage from stroke, therefore making targeting tau-dependent processes relevant beyond progressive age-related neurodegenerative disorders, such as AD. The gene discussed is MAPT; the disease is Alzheimer disease.